A Novel High-Precision Method for Diagnosing Hyperparathyroidism


Executive Summary


Parathyroid hormone (PTH) is a critical regulator of circulating calcium concentration in blood plasma. Maintaining normal circulating calcium levels is essential for cell signaling and bone metabolism. Hyperparathyroidism due to excessive secretion of PTH disrupts these signaling networks. Current methods of quantifying PTH in plasma lack accuracy as they are unable to detect all the different forms of PTH. A novel assay developed by researchers at Michigan State University overcomes these limitations by detecting concentration levels of all active forms of PTH in plasma samples, providing higher precision for diagnosing hyperparathyroidism.


Description of Technology


This new method simultaneously quantifies intact, truncated, and oxidized variants of PTH in plasma samples. By detecting all active forms of PTH in the plasma, this technique allows for a more precise diagnosis of hyperparathyroidism in the clinic, overcoming the limitations of other available methods.


Key Benefits

  • Detection of all active forms of parathyroid hormone in a plasma sample
  • Higher diagnostic accuracy



  • Diagnostic tools
  • Detection of hyperparathyroidism


Patent Status: 


Under review.


Licensing Rights Available


Full licensing rights available.


Inventors: Gavin Edmund Reid, Li Cui


Tech ID: TEC2015-0040


Alternative contact due to temporary leave:


Nina (Isi) Davis, Technology Marketing Manager, email: davisnin@msu.edu, phone (direct): (517)884-1829. 


Patent Information:


For Information, Contact:

Randy Ramharack
Technology Manager
Michigan State University
Gavin Reid
Li Cui